Eisai (ESALY) and Biogen (BIIB) announced that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology, for review following a standard timeline.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Biogen says FDA to convene advisory committee meeting for tofersen
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eisai submits marketing authorization application for lecanemab in Japan
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue